Clinical trials: in Portugal
Gastric Neoplasms, Gastric Dysplasia
Epinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal Dissection
This prospective, randomized, single-center trial compares two epinephrine concentrations (1:100,000 and 1:500,000) in the submucosal injection solution used during gastric endoscopic submucosal dissection.
- Trial name
- EPI-DILUTE (NCT07920068)
- Testing
- Epinephrine 1:100,000, Epinephrine 1:500,000
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Unidade Local de Saúde do Alto Ave, EPE
Sjogren's Syndrome
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
- Trial name
- NCT04968912
- Testing
- Nipocalimab, Standard of Care Treatment
- Where
- 69 sites in United States, France and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with…
- Conditions
- PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
- Trial name
- ReDiscover-2 (NCT06982521)
- Testing
- Zovegalisib, Capivasertib, Fulvestrant
- Where
- 254 sites in United States, Argentina and 25 more
- Volunteers
- 540 people
- Sponsor
- Relay Therapeutics, Inc.
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS…
- Trial name
- Krascendo 2 (NCT06793215)
- Testing
- Divarasib, Pembrolizumab, Pemetrexed
- Where
- 299 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
- Trial name
- BREnnA (NCT07413939)
- Testing
- RO7771950, Tucatinib, Trastuzumab
- Where
- 219 sites in United States, Argentina and 24 more
- Volunteers
- 650 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with…
- Trial name
- PARAISO (NCT07174310)
- Testing
- Prasinezumab
- Where
- 192 sites in United States, Australia and 15 more
- Volunteers
- 900 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- LUCERNA (NCT06901531)
- Testing
- zolbetuximab, Pembrolizumab, Capecitabine
- Where
- 253 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or…
- Trial name
- MajesTEC-9 (NCT05572515)
- Testing
- Teclistamab, Pomalidomide, Bortezomib
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 614 people
- Sponsor
- Janssen Research & Development, LLC
Stress (Psychology), Anxiety
HRVB for Stress and Anxiety During Dentistry Students' Clinical Transition
The goal of this clinical trial is to learn if Heart Rate Variability Biofeedback (HRVB) can reduce stress and anxiety in dentistry students during the transition from pre-clinical training to clinical practice.
- Conditions
- Stress (Psychology), Anxiety, Psychological Distress
- Trial name
- HRVB-MIMD (NCT07415915)
- Testing
- Heart Rate Variability Biofeedback (HRVB) Training
- Where
- Portugal
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Egas Moniz - Cooperativa de Ensino Superior, CRL
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less…
- Trial name
- NCT07817875
- Testing
- Tirzepatide
- Where
- 82 sites in United States, Belgium and 8 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Prostatic Neoplasms
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination…
- Trial name
- AMPLITUDE (NCT04497844)
- Testing
- Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone
- Where
- 387 sites in United States, Argentina and 31 more
- Volunteers
- 696 people
- Sponsor
- Janssen Research & Development, LLC
Melanoma, Ovarian Cancer
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
The purpose of this study is to find out which way of giving high-dose radiation works best for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Bone
- Trial name
- NCT01223248
- Testing
- IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
- Where
- 4 sites in United States, Italy and 1 more
- Volunteers
- 220 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative…
- Trial name
- ELEGANT (NCT06492616)
- Testing
- Elacestrant, Anastrozole, Letrozole
- Where
- 555 sites in United States, Argentina and 26 more
- Volunteers
- 4,556 people
- Sponsor
- Stemline Therapeutics, Inc.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
- Trial name
- NCT06128629
- Testing
- NTLA-2001
- Where
- 138 sites in United States, Argentina and 24 more
- Volunteers
- 1,200 people
- Sponsor
- Intellia Therapeutics
Social Media Addiction, Craving to Use Social Media
tDCS for Social Media Addiction
The goal of this clinical trial is to learn whether transcranial direct current stimulation (tDCS), a non-invasive brain stimulation, can reduce "craving" and problematic levels of social media/internet use in university…
- Conditions
- Social Media Addiction, Craving to Use Social Media, Craving, Internet Addiction
- Trial name
- tDCS4SMA (NCT07410104)
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- Portugal
- Volunteers
- 61 people
- Sponsor
- Egas Moniz - Cooperativa de Ensino Superior, CRL
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.